Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis
- PMID: 20413740
- PMCID: PMC2909661
- DOI: 10.1161/STROKEAHA.109.573410
Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis
Abstract
Background and purpose: Although a lower serum homocysteine concentration is associated with a reduced risk of stroke in epidemiologic studies, randomized, controlled trials have yielded mixed findings regarding the effect of therapeutic homocysteine lowering on stroke prevention. We performed a meta-analysis of randomized, controlled trials to assess the efficacy of folic acid supplementation in the prevention of stroke.
Methods: Salient trials were identified by formal literature search. Relative risk (RR) with 95% CI was used as a measure of the association between folic acid supplementation and risk of stroke, after pooling data across trials in a fixed-effects model.
Results: The search identified 13 randomized, controlled trials that had enrolled 39 005 participants for folic acid therapy to reduce homocysteine in which stroke was reported as an outcome measure. Across all trials, folic acid supplementation was associated with a trend toward mild benefit that did not reach statistical significance in reducing the risk of stroke (RR=0.93; 95% CI, 0.85-1.03; P=0.16). The RR for nonsecondary prevention trials was 0.89 (95% CI, 0.79-0.99; P=0.03). In stratified analyses, a greater beneficial effect was seen in the trials testing combination therapy of folic acid plus vitamins B6 and B12 (RR=0.83; 95% CI, 0.71-0.97; P=0.02) and in the trials that disproportionately enrolled male patients (men:women >2; RR=0.84; 95% CI, 0.74-0.94; P=0.003).
Conclusions: Folic acid supplementation did not demonstrate a major effect in averting stroke. However, potential mild benefits in primary stroke prevention, especially when folate is combined with B vitamins and in male patients, merit further investigation.
Conflict of interest statement
Conflict of interest: We declare that we have no conflict of interest.
Figures
Comment in
-
Meta analysis suggests that folic acid supplementation does not reduce risk of stroke, but there may be some benefit when given in combination with vitamins B6 and B12 and in primary prevention.Evid Based Med. 2010 Dec;15(6):168-70. doi: 10.1136/ebm1120. Epub 2010 Aug 25. Evid Based Med. 2010. PMID: 20797992 No abstract available.
Similar articles
-
Homocysteine-lowering interventions for preventing cardiovascular events.Cochrane Database Syst Rev. 2017 Aug 17;8(8):CD006612. doi: 10.1002/14651858.CD006612.pub5. Cochrane Database Syst Rev. 2017. PMID: 28816346 Free PMC article. Review.
-
[Meta-analysis on effect of combined supplementation of folic acid, vitamin B12 and B6 on risk of cardio-cerebrovascular diseases in randomized control trials].Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Jul;37(7):1028-34. doi: 10.3760/cma.j.issn.0254-6450.2016.07.024. Zhonghua Liu Xing Bing Xue Za Zhi. 2016. PMID: 27453118 Chinese.
-
Efficacy of Supplementation with B Vitamins for Stroke Prevention: A Network Meta-Analysis of Randomized Controlled Trials.PLoS One. 2015 Sep 10;10(9):e0137533. doi: 10.1371/journal.pone.0137533. eCollection 2015. PLoS One. 2015. PMID: 26355679 Free PMC article.
-
The effect of folate fortification on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-analysis.Public Health Nutr. 2015 Jun;18(8):1514-21. doi: 10.1017/S1368980014002134. Epub 2014 Oct 17. Public Health Nutr. 2015. PMID: 25323814 Free PMC article. Review.
-
Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials.Lancet. 2011 Aug 13;378(9791):584-94. doi: 10.1016/S0140-6736(11)60872-6. Epub 2011 Jul 29. Lancet. 2011. PMID: 21803414 Free PMC article.
Cited by
-
Hyperhomocysteinemia in Adult Patients: A Treatable Metabolic Condition.Nutrients. 2023 Dec 30;16(1):135. doi: 10.3390/nu16010135. Nutrients. 2023. PMID: 38201964 Free PMC article. Review.
-
ALDH7A1 rs12514417 polymorphism may increase ischemic stroke risk in alcohol-exposed individuals.Nutr Metab (Lond). 2022 Oct 18;19(1):70. doi: 10.1186/s12986-022-00702-3. Nutr Metab (Lond). 2022. PMID: 36258220 Free PMC article.
-
Hyperhomocysteinemia Is a Predictor for Poor Postoperative Angiogenesis in Adult Patients With Moyamoya Disease.Front Neurol. 2022 Jun 2;13:902474. doi: 10.3389/fneur.2022.902474. eCollection 2022. Front Neurol. 2022. PMID: 35720075 Free PMC article.
-
Endothelial Dysfunction and Hyperhomocysteinemia-Linked Cerebral Small Vessel Disease: Underlying Mechanisms and Treatment Timing.Front Neurol. 2021 Nov 24;12:736309. doi: 10.3389/fneur.2021.736309. eCollection 2021. Front Neurol. 2021. PMID: 34899561 Free PMC article. Review.
-
Opicapone Protects Against Hyperhomocysteinemia-Induced Increase in Blood-Brain Barrier Permeability.Neurotox Res. 2021 Dec;39(6):2018-2028. doi: 10.1007/s12640-021-00429-8. Epub 2021 Oct 28. Neurotox Res. 2021. PMID: 34709593
References
-
- Curro M, Condello S, Caccamo D, Ientile R. Homocysteine-induced toxicity increases TG2 expression in neuro2a cells. Amino Acids. 2009;36:725–730. - PubMed
-
- Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050. - PubMed
-
- Ridker PM, Manson JE, Buring JE, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281:1817–1821. - PubMed
-
- Khan U, Crossley C, Kalra L, Rudd A, Markus HS. Homocysteine and its relationship to stroke subtypes in a UK black population: The South London ethnicity and stroke study. Stroke. 2008;39:2943–2949. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical